Madison-based Stratatech Corp. has been awarded another federal grant, this one for $4 million for development of its genetically engineered therapeutic human skin substitute with enhanced antimicrobial and angiogeneic properties for use in the treatment of type 1 diabetic skin ulcers.
….The UW-Madison spin-off, which was established in 2000, also is working with the U.S. Food and Drug Administration to evaluate the safety and efficacy of its flagship StrataGraft engineered skin tissue product for the treatment of burn victims.
Stratatech’s products are based on a patented, unique source of pathogen-free human skin cells identified at UW-Madison as being able to multiply indefinitely.